Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?

Leuk Lymphoma. 2018 May;59(5):1163-1171. doi: 10.1080/10428194.2017.1375102. Epub 2017 Sep 13.

Abstract

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. Patients with stage I disease are usually treated with radiotherapy (RT). In previous studies, mostly from the pre positron emission tomography-computed tomography (PET-CT) era, the 5 year progression-free survival (PFS) and overall survival (OS) rates of stage I disease were 60-80% and 80-93%, respectively. This study retrospectively evaluated the outcome of stage I FL which was treated with involved field RT in the PET-CT era between 2002 and 2015. Ninety-one patients were enrolled. Five year PFS and OS rates were 73% and 97%, respectively. Relapse occurred in 19 (21%) patients, 74% occurring outside the radiation field. In conclusion, PET-CT staging of clinical stage I FL may contribute to the improved prognosis in patients treated with RT compared to historical cohorts, possibly due to better identification of "genuine" stage I disease.

Keywords: Follicular lymphoma; immunotherapy; positron emission tomography; radiotherapy; rituximab.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Humans
  • Lymphoma, Follicular / diagnostic imaging
  • Lymphoma, Follicular / pathology*
  • Lymphoma, Follicular / radiotherapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiopharmaceuticals*
  • Radiotherapy / methods*
  • Retrospective Studies
  • Survival Rate

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18